School of Basic Medical Sciences, Anhui Medical University, Hefei 230000, Anhui, China;State Key Laboratory of Pathogen and Biosecurity, Institute of Microbiology and Epidemiology, Academy of Military Medicine, Academy of Military Sciences, Beijing 100071, China 在期刊界中查找 在百度中查找 在本站中查找
State Key Laboratory of Pathogen and Biosecurity, Institute of Microbiology and Epidemiology, Academy of Military Medicine, Academy of Military Sciences, Beijing 100071, China;School of Medicine, Tsinghua University, Beijing 100084, China 在期刊界中查找 在百度中查找 在本站中查找
School of Basic Medical Sciences, Anhui Medical University, Hefei 230000, Anhui, China;State Key Laboratory of Pathogen and Biosecurity, Institute of Microbiology and Epidemiology, Academy of Military Medicine, Academy of Military Sciences, Beijing 100071, China 在期刊界中查找 在百度中查找 在本站中查找
School of Basic Medical Sciences, Anhui Medical University, Hefei 230000, Anhui, China;State Key Laboratory of Pathogen and Biosecurity, Institute of Microbiology and Epidemiology, Academy of Military Medicine, Academy of Military Sciences, Beijing 100071, China 在期刊界中查找 在百度中查找 在本站中查找
The messenger RNA (mRNA) platform has emerged as a novel nucleic acid technology for the development of vaccines and antibodies in the last decade. mRNA vaccines are superior to conventional vaccines because of safe administration, high potency, short development cycle and low cost of manufacturing. The mRNA-encoded antibodies prevail over other antibody expression platforms because of the high level and long duration of protein expression. Owing to the recent innovations in mRNA modification and delivery, mRNA platform has been developing rapidly and become a promising tool in vaccine development and cancer therapy. It is a miraculous scientific triumph to develop novel mRNA vaccines against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), which paves the way to a promising future of this field. Here, we overview the ongoing efforts for the optimization of mRNA approaches, with an emphasis on the research progress of mRNA vaccines and mRNA-encoded antibodies for infectious diseases. Furthermore, we put forward the key issues facing the mRNA platform in combating infectious diseases.
